DK4073097T3 - Nye insulinanaloger og anvendelser heraf - Google Patents

Nye insulinanaloger og anvendelser heraf Download PDF

Info

Publication number
DK4073097T3
DK4073097T3 DK20820432.1T DK20820432T DK4073097T3 DK 4073097 T3 DK4073097 T3 DK 4073097T3 DK 20820432 T DK20820432 T DK 20820432T DK 4073097 T3 DK4073097 T3 DK 4073097T3
Authority
DK
Denmark
Prior art keywords
insulin analogues
new insulin
new
analogues
insulin
Prior art date
Application number
DK20820432.1T
Other languages
English (en)
Inventor
Peter Madsen
Frantisek Hubalek
Mathias Norrman
Helle Birk Olsen
Jeppe Sturis
Thomas Børglum Kjeldsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of DK4073097T3 publication Critical patent/DK4073097T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK20820432.1T 2019-12-11 2020-12-10 Nye insulinanaloger og anvendelser heraf DK4073097T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19215315 2019-12-11
PCT/EP2020/085541 WO2021116292A1 (en) 2019-12-11 2020-12-10 Novel insulin analogues and uses thereof

Publications (1)

Publication Number Publication Date
DK4073097T3 true DK4073097T3 (da) 2024-08-19

Family

ID=68886882

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20820432.1T DK4073097T3 (da) 2019-12-11 2020-12-10 Nye insulinanaloger og anvendelser heraf

Country Status (29)

Country Link
US (3) US11498951B2 (da)
EP (2) EP4480492A3 (da)
JP (2) JP6995284B2 (da)
KR (1) KR102427426B1 (da)
CN (1) CN114787184A (da)
AR (1) AR120717A1 (da)
AU (1) AU2020402135A1 (da)
BR (1) BR112022009510A2 (da)
CA (1) CA3159114A1 (da)
CL (1) CL2023000086A1 (da)
CO (1) CO2022007273A2 (da)
DK (1) DK4073097T3 (da)
ES (1) ES2985989T3 (da)
FI (1) FI4073097T3 (da)
HR (1) HRP20241042T1 (da)
HU (1) HUE067827T2 (da)
IL (2) IL319162A (da)
LT (1) LT4073097T (da)
MA (1) MA58093B1 (da)
MX (2) MX2022006251A (da)
MY (1) MY208364A (da)
PE (1) PE20221260A1 (da)
PH (1) PH12022551094A1 (da)
PL (1) PL4073097T3 (da)
PT (1) PT4073097T (da)
RS (1) RS65822B1 (da)
SI (1) SI4073097T1 (da)
TW (1) TWI773009B (da)
WO (1) WO2021116292A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR106364A1 (es) 2015-08-25 2018-01-10 Novo Nordisk As Derivados de insulina y sus usos médicos
DK4073097T3 (da) * 2019-12-11 2024-08-19 Novo Nordisk As Nye insulinanaloger og anvendelser heraf
KR20230057686A (ko) 2021-10-22 2023-05-02 주식회사 엘지에너지솔루션 캡 어셈블리 및 이를 포함하는 이차 전지

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
CA2070814A1 (en) 1989-12-21 1991-06-22 Klavs H. Jorgensen Insulin preparations containing nicotinic acid or nicotinamide
SI0792290T1 (en) 1993-09-17 2001-12-31 Novo Nordisk As Acylated insulin
IL114160A (en) 1994-06-17 2006-12-31 Novo Nordisk As Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5922678A (en) 1996-06-28 1999-07-13 Eli Lilly And Company Methods for treating diabetes
ES2258797T3 (es) 1996-12-20 2006-09-01 Novo Nordisk A/S Proteinas con extension n-terminal expresadas en la levadura.
JP3764174B2 (ja) 1997-03-20 2006-04-05 ノボ ノルディスク アクティーゼルスカブ 肺用組成物において使用するための亜鉛非含有のインスリン結晶
JP2001521004A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 脂肪酸−アシル化インスリン類似体
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
JP5202338B2 (ja) 2006-02-27 2013-06-05 ノボ・ノルデイスク・エー／エス 新規インシュリン誘導体
JP2009530243A (ja) 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー／エス アシル化単鎖インスリン
ITRG20070003A1 (it) 2007-07-17 2009-01-18 Salvatore Lucifora Metodo e sistema informatico per analizzare le prestazioni e dimensionare una cella underlay/overlay di un sistema di telecomunicazione cellulare
CN101778862B (zh) 2007-08-13 2014-12-17 诺沃-诺迪斯克有限公司 快速作用的胰岛素类似物
EP2178910B1 (en) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
ES2548304T3 (es) 2007-08-15 2015-10-15 Novo Nordisk A/S Análogos de la insulina que contienen una fracción acilo y alquilenglicol
JP5762001B2 (ja) * 2008-03-14 2015-08-12 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化インスリンアナログ
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
US9242011B2 (en) 2008-04-01 2016-01-26 Novo Nordisk A/S Insulin albumin conjugates
EP2448962B1 (en) 2009-06-30 2016-10-19 Novo Nordisk A/S Insulin derivatives
US8865647B2 (en) 2009-11-02 2014-10-21 Novo Nordisk A/S Pharmaceutical solution of non covalently bound albumin and acylated insulin
WO2011161124A1 (en) 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
US9068013B2 (en) 2010-07-28 2015-06-30 Smart Cells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
WO2012049307A2 (en) 2010-10-15 2012-04-19 Novo Nordisk A/S Novel n-terminally modified insulin derivatives
US9260503B2 (en) 2011-06-15 2016-02-16 Novo Nordisk A/S Multi-substituted insulins
KR20150021011A (ko) 2011-10-27 2015-02-27 케이스 웨스턴 리저브 유니버시티 초고도 농축된, 속효성 인슐린 유사체 제형
RU2014127270A (ru) 2011-12-15 2016-02-10 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Аналог человеческого инсулина и его ацилированное производное
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
AU2014329567B2 (en) 2013-10-04 2019-07-25 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
AR106364A1 (es) * 2015-08-25 2018-01-10 Novo Nordisk As Derivados de insulina y sus usos médicos
US20190010206A1 (en) * 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
CN105440125B (zh) 2015-11-25 2019-09-24 华润昂德生物药业有限公司 地特胰岛素或其类似物的制备方法
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
DK4073097T3 (da) * 2019-12-11 2024-08-19 Novo Nordisk As Nye insulinanaloger og anvendelser heraf

Also Published As

Publication number Publication date
US11498951B2 (en) 2022-11-15
US20230192801A1 (en) 2023-06-22
IL292762B1 (en) 2025-06-01
TW202136289A (zh) 2021-10-01
IL292762B2 (en) 2025-10-01
PL4073097T3 (pl) 2024-10-28
TWI773009B (zh) 2022-08-01
EP4073097B1 (en) 2024-07-03
CO2022007273A2 (es) 2022-08-19
US20240141011A1 (en) 2024-05-02
MY208364A (en) 2025-05-01
EP4073097A1 (en) 2022-10-19
ES2985989T3 (es) 2024-11-08
PH12022551094A1 (en) 2024-06-24
CA3159114A1 (en) 2021-06-17
RS65822B1 (sr) 2024-09-30
IL292762A (en) 2022-07-01
US12122818B2 (en) 2024-10-22
PE20221260A1 (es) 2022-08-16
EP4480492A3 (en) 2025-03-19
CL2023000086A1 (es) 2023-08-04
IL319162A (en) 2025-04-01
MX2023000398A (es) 2023-02-02
JP2021091685A (ja) 2021-06-17
SI4073097T1 (sl) 2024-09-30
US12152063B2 (en) 2024-11-26
AU2020402135A1 (en) 2022-06-02
BR112022009510A2 (pt) 2022-08-16
PT4073097T (pt) 2024-08-16
MA58093B1 (fr) 2024-09-30
LT4073097T (lt) 2024-09-10
HUE067827T2 (hu) 2024-11-28
KR102427426B1 (ko) 2022-08-01
KR20210141748A (ko) 2021-11-23
EP4480492A2 (en) 2024-12-25
JP6995284B2 (ja) 2022-01-14
US20210179685A1 (en) 2021-06-17
JP2021119193A (ja) 2021-08-12
FI4073097T3 (fi) 2024-08-13
HRP20241042T1 (hr) 2024-11-08
CN114787184A (zh) 2022-07-22
MX2022006251A (es) 2022-06-22
AR120717A1 (es) 2022-03-09
WO2021116292A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
DK3727426T3 (da) Incretinanaloger og anvendelser deraf
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
IL268593A (en) Polypeptide variants and uses thereof
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3508580T3 (da) Ny promotor og anvendelse deraf
DK4238511T3 (da) Hjerteklapforseglingsindretninger og leveringsindretninger dertil
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3368085T3 (da) Modificerede alginater til anti-fibrotiske materialer og anvendelser
EP3341404C0 (en) NEW INSULIN ANALOGS AND THEIR USE
DK3250692T3 (da) Promotor og anvendelser deraf
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3322430T3 (da) Antiinflammatoriske peptider, og anvendelser deraf
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3813946T3 (da) Rapamycin-analoger og anvendelser deraf
DK3302630T3 (da) Sprøjtestøtte og autoinjektor
DK3447056T3 (da) Multikinasehæmmerforbindelse, krystalform og anvendelse deraf
DK3612579T3 (da) Pultrudat, fremstilling og anvendelse heraf
DK3532459T3 (da) Lsd1-hæmmere og medicinske anvendelser deraf
DK3263565T3 (da) Cyklisk aminderivat og farmaceutisk anvendelse deraf
DK3621694T5 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3743106T3 (da) Influenzavirusvacciner og anvendelser deraf
DK3922266T3 (da) Toll-like-receptor-7- eller -8-agonist-kolesterolkompleks og anvendelse deraf
EP3351533C0 (en) BIARYL DERIVATIVE AND MEDICINE CONTAINING IT
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3325618T3 (da) Hidtil ukendte trypsin-isoformer og anvendelse deraf